AEGiS-AP: Gilead, Bristol-Myers to Market HIV Drug: Gilead Sciences and Bristol-Myers Squibb Agree to Market HIV Drug Atripla in Europe

Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.

Gilead, Bristol-Myers to Market HIV Drug: Gilead Sciences and Bristol-Myers Squibb Agree to Market HIV Drug Atripla in Europe

Associated Press - Tuesday, December 11, 2007

FOSTER CITY, Calif. (AP) -- Bristol-Myers Squibb Co. and biopharmaceutical company Gilead Sciences Inc. said Tuesday they have agreed to collaborate to commercialize the drug Atripla in Europe for the treatment of adults infected with HIV.

If approved by the European Commission, Atripla would represent the first and only once-daily single-tablet regimen for HIV infection in the European Union. The companies expect the European Commission to issue its decision by the end of the year.

Atripla is a one-pill combination of Gilead's Truvada, which includes Viread and Emtriva, and Bristol-Myers Squibb's Sustiva.

Bristol-Myers Squibb and Gilead will share responsibility for commercializing Atripla throughout the European Union and some other European countries.

Under the terms of the deal, Gilead will record revenue from future sales of Atripla in most of the European countries, while Bristol-Myers Squibb will record a percentage of revenue based on the contribution represented by its product.

Atripla is currently sold in the U.S. and Canada through a joint venture between Bristol-Myers Squibb and Gilead. The drug was approved by the U.S. Food and Drug Administration in July 2006 and by Health Canada in October 2007.

Previously, Gilead and Merck announced a collaboration to distribute Atripla in developing countries.

071211
AP071225

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .